SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy.

ABSTRACT:

Objective

To compare the frequency of replication-competent virologic rebound with and without nirmatrelvir-ritonavir treatment for acute COVID-19. Secondary aims were to estimate the validity of symptoms to detect rebound and the incidence of emergent nirmatrelvir-resistance mutations after rebound.

Design

Observational cohort study.

Setting

Multicenter healthcare system in Boston, Massachusetts.

Participants

We enrolled ambulatory adults with a positive COVID-19 test and/or a prescription for nirmatrelvir-ritonavir.

Exposures

Receipt of 5 days of nirmatrelvir-ritonavir treatment versus no COVID-19 therapy.

Main outcome and measures

The primary outcome was COVID-19 virologic rebound, defined as either (1) a positive SARS-CoV-2 viral culture follo

SUBMITTER: Edelstein GE 

PROVIDER: S-EPMC10327262 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature